title: Novel cardiovascular drugs in clinical trials.
abstract: Cardiovascular diseases remain a major cause of morbidity and mortality worldwide, regardless of the recent advances in medical and surgical treatment, for as life expectancy in the developed countries increases, cardiovascular conditions affecting the elderly also rises. Atherosclerosis and cardiovascular diseases take a huge toll on the society, making them the leading cause of death in developed countries. Phenomenal advances in the pathophysiology of cardiovascular disease and the molecular signaling pathways has revealed the role of endothelial dysfunction involved therein and thus has raised the possibility of novel therapeutic targets. Such potential cellular targets include the vascular smooth muscle cells, monocyte/macrophage cell lines, platelets, and endothelial cells. Certain studies affirm that antiplatelet agents, antioxidant therapies, amino acid supplementation, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers may prevent or slow the progression of the disease process. The race is on for new medicines that can treat and prevent heart attacks and strokes, arising out of atherosclerosis, which kills nearly 1 million people a year in the U.S.A alone.
authors.affiliation: Department of Pharmacology SCB Medical College & Hospital, Cuttack, Odisha, India.
authors.forename: Sasmita
authors.initials: S
authors.lastname: Biswal
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001547:Benzaldehydes / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D065128:Endothelin Receptor Antagonists; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007555:Isoxazoles / Q000627:therapeutic use; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use; D008666:Metalloendopeptidases / Q000627:therapeutic use; D023303:Oxazolidinones / Q000627:therapeutic use; D010091:Oximes / Q000627:therapeutic use; D064801:Phospholipase A2 Inhibitors / Q000627:therapeutic use; D011341:Probucol / Q000031:analogs & derivatives / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides
chemical_list: D000924:Anticholesteremic Agents; D001547:Benzaldehydes; D002317:Cardiovascular Agents; D065128:Endothelin Receptor Antagonists; D005343:Fibrinolytic Agents; D007155:Immunologic Factors; D007555:Isoxazoles; D016859:Lipoxygenase Inhibitors; D008666:Metalloendopeptidases; D023303:Oxazolidinones; D010091:Oximes; D064801:Phospholipase A2 Inhibitors; D011341:Probucol; D011743:Pyrimidines; D011804:Quinolines; D013876:Thiophenes; C079315:2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; C006253:pirinixic acid; C436755:alfimeprase; C471047:succinobucol; C106276:sitaxsentan; C530884:anacetrapib; C529040:darapladib; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides